Fig. 5: The AZD6738 ATR inhibitor enhances the antitumour efficacy of the olaparib plus IR combination treatment in subcutaneous grafts, but not in lung or head and neck orthotopic tumours. | British Journal of Cancer

Fig. 5: The AZD6738 ATR inhibitor enhances the antitumour efficacy of the olaparib plus IR combination treatment in subcutaneous grafts, but not in lung or head and neck orthotopic tumours.

From: Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models

Fig. 5

Tumour-bearing mice were allocated to treatment groups on day 1. Olaparib (25 mg/kg) and/or AZD6738 (15 mg/kg) were administered daily from day 1 to day 6. Irradiated mice received four fractions of 4.5 Gy (local irradiation on days 1, 2, 4 and 5). a LL2-luc subcutaneous grafts (n = 11–14). b LL2-luc lung orthotopic tumours (representative image of bioluminescence capture in the middle of the panel, n = 6–34). c TC1-luc head and neck orthotopic tumours (representative image of bioluminescence capture in the middle of the panel, n = 10–30). For a, b and c, tumour growth (upper- left panel, mean ± SEM or median), Kaplan–Meier analysis of mouse survival (upper-right panel) and statistical analyses (bottom) are depicted. For c, some mice were additionally scored for mucositis using a macroscopic scoring system (mean ± SEM, n = 10–13, lower-right panel).

Back to article page